A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group study
J. Wendall Goodwin(Cancer Research for the Ozarks), Jeannette J. Townsend(The University of Texas MD Anderson Cancer Center), Benjamin K. Stafford(University of Michigan), Kurt A. Jaeckle(Jacksonville College), John Crowley(AbbVie (United States)), Harmon J. Eyre(American Cancer Society)
Cited by 179
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
American Cancer Society Guidelines for the Early Detection of Cancer
|CA A Cancer Journal for Clinicians|2002|1.6k
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
|Journal of Clinical Oncology|2013|1.1k